52
Participants
Start Date
December 31, 2010
Primary Completion Date
September 30, 2012
Study Completion Date
April 30, 2013
NIC002 in Aluminum hydroxide (Alum)
Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
Placebo Vaccine - Aluminum hydroxide
Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
Wake Forest University Health Sciences, Winston-Salem
Duke Center for Nicotine & Smoking Cessation Research, Durham
Collaborators (1)
Wake Forest University Health Sciences
OTHER
Novartis Pharmaceuticals
INDUSTRY
Alexey Mukhin
OTHER